Provectus Biopharmaceuticals, Inc. to Hold Conference Call Today to Detail Outline of Phase 3 Clinical Trial of PV-10 in Mela...
June 19 2014 - 6:00AM
Business Wire
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT)
(http://www.pvct.com), a development-stage oncology and dermatology
biopharmaceutical company, wishes to remind interested parties that
it will hold a conference call today, Thursday, June 19, 2014 at
4:00 p.m. EDT.
Management will discuss the outline of the Company’s planned
phase 3 study of PV-10 in the treatment of melanoma and
developments in the use of PV-10 in other cancer indications
including PV-10 in combination as appropriate. It will also review
PV-10 data presented in Chicago at ASCO earlier in the month on
June 2nd, as well as provide updates on PH-10 and news regarding
its use. Management will also discuss its potential plans to
monetize its PV-10 and PH-10 assets with various contemplated
license and co-development transactions.
The Company has submitted PV-10 phase 2 melanoma study results
to www.clinicaltrials.gov and will announce when these are
published and become publicly available. In the interim, the
Company is providing data presented at ASCO via this link:
http://www.pvct.com/publications/ASCO-Poster-2014.pdf, which
contains the phase 3 study outline that the Company will discuss on
today’s conference call. Moffitt Cancer Center data presented at
ASCO is expected to be published in a future peer-reviewed journal
publication.
Those who wish to participate in the conference call may
telephone 877-407-4019 from the U.S. International callers may
telephone 201-689-8337 approximately 15 minutes before the call. A
webcast will also be available at www.pvct.com.
A digital replay will be available by telephone approximately
two hours after the completion of the call until August 19, 2014,
and may be accessed by dialing 877-660-6853 from the U.S. or
201-612-7415 for International callers, and using the Conference
ID#13584727.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug
for cancer, is designed for injection into solid tumors
(intralesional administration), thereby reducing potential for
systemic side effects. Its oncology focus is on melanoma, breast
cancer and cancers of the liver. The Company has received orphan
drug designations from the FDA for its melanoma and hepatocellular
carcinoma indications. PH-10, its topical investigational drug for
dermatology, is undergoing clinical testing for psoriasis and
atopic dermatitis. Provectus has completed phase 2 trials of PV-10
as a therapy for metastatic melanoma, and of PH-10 as a topical
treatment for atopic dermatitis and psoriasis. Information about
these and the Company's other clinical trials can be found at the
NIH registry, www.clinicaltrials.gov. For additional information
about Provectus please visit the Company's website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This press release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2013, and in our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2014), and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with a
phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma
and the costs associated with such a trial if it is necessary;
- our determination whether to license
PV-10, our melanoma drug product candidate, and other solid tumors
such as liver cancer, if such licensure is appropriate considering
the timing and structure of such a license, or to commercialize
PV-10 on our own to treat melanoma and other solid tumors such as
liver cancer;
- our ability to license our dermatology
drug product candidate, PH-10, on the basis of our phase 2 atopic
dermatitis and psoriasis results, which are in the process of being
further developed in conjunction with mechanism of action studies;
and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper,
866-594-5999 #30CFO, COOorPorter, LeVay & Rose, Inc.Investor
RelationsMarlon Nurse, 212-564-4700DM, SVPorMedia RelationsBill
Gordon, 212-724-6312
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024